A Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC [doxorubicin + cyclophosphamide] Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response.

Trial Profile

A Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC [doxorubicin + cyclophosphamide] Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Jun 2016

At a glance

  • Drugs Lapatinib (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel; Trastuzumab
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Jun 2016 Results assessing 5 year overall survival and 5 year recurrence-free interval (RFI) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 03 Jun 2016 Planned End Date changed from 1 Mar 2016 to 1 Mar 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top